Total Marrow Irradiation Provides Greater Precision, Fewer Side Effects

SUNNYVALE, California, June 10, 2015 /PRNewswire/ --

10-Year Anniversary of First Total Marrow Irradiation Delivery with the TomoTherapy^® System Illustrates Growing Impact of Groundbreaking Approach

This month marks the 10-year anniversary of the first successful total marrow irradiation (TMI) using the TomoTherapy^® System. This procedure was performed at City of Hope in Duarte, California. As a result of continuing research and use of the system for TMI, numerous centers around the world have adopted the approach, once considered to be impossible because of limitations inherent to conventional radiation therapy systems.

TMI is an advanced form of total body irradiation, which has traditionally been an important part of bone marrow transplants (BMT). People with certain types of cancers or other diseases including leukemias, lymphomas and multiple myeloma may undergo a BMT as part of their treatment. Before the transplant, chemotherapy and/or radiation may be given to neutralize any cancer in the marrow.

Traditional approaches to total body irradiation resulted in the same dose of radiation delivered to the entire body, not just the bone marrow, causing damage to healthy organs and side effects ranging from nausea and diarrhea to cataracts and secondary malignancies. In contrast, the TomoTherapy System delivers small radiation "beamlets" from 360 degrees around the patient, allowing for greater control of the prescription dose so it conforms precisely to the target. This enables physicians to irradiate the bone marrow with larger doses of radiation while sparing nearby normal, healthy organs and limiting radiation side effects. Also, the system's CT scanner-based design allows efficient delivery of radiation to very large areas without field matching. These attributes are unique to the TomoTherapy System and facilitate its use for TMI as an alternative to total body irradiation.

The TomoTherapy System is the only radiation system specifically designed for image-guided intensity-modulated radiation therapy (IMRT). More than 950 scientific articles have been published on TomoTherapy technology, with many addressing the clinical value and patient benefit of this treatment modality across a broad range of indications. The system offers clinicians the flexibility to deliver treatment in a helical mode or from clinician-specified beam angles with TomoDirect™ Mode. These unique features, combined with daily 3D image guidance, enable physicians to:

• Deliver highly accurate, individualized dose distributions to any tumor, at its true location, during each treatment; and
• Treat all standard radiation therapy indications including breast, prostate, lung and head and neck cancers, in addition to complex treatments such as total marrow irradiation.

For more information visit http://www.accuray.com/solutions/treatment-delivery/tomotherapy-treatment-delivery/h-series.

Quotes 

Joshua H. Levine, president and chief executive officer of Accuray: "The TomoTherapy^® System is a radiotherapy technology that allows entirely new approaches, while also bringing the highest quality care to the widest range of patients. In honor of National Cancer Survivor's Day, June 7, 2015, we want to recognize the clinicians worldwide who are using technologies such as the TomoTherapy System to improve the way cancer is managed and bring new hope to people who previously would have been without options."

Dr. Stefano Vagge, MD, Ph.D: "The A.O.U. IRCCS San Martino IST National Cancer Research Institute of Genoa is dedicated to using innovative technologies to help cancer patients. Six years ago we tried to set a new standard of care in Europe when we began using the TomoTherapy System for TMI, an innovative approach that has become a critical part of our practice. We have treated more than fifty patients in the setting of autologous and allogenic stem cell transplantation for high-risk leukemia, lymphoma and multiple myeloma. In our clinical experience, the TomoTherapy System allows us to work collaboratively with the Genoa Hematopoietic Stem Cell Transplantation Department, a vanguard in Europe, to significantly reduce radiation toxicity and implement new treatment approaches in hematology."

About the TomoTherapy System 

The Accuray TomoTherapy System enables physicians to efficiently customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.

About Accuray 

Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com.

Safe Harbor Statement 

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in and future contributions to radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, the company's reports on Form 10-Q, filed on November 7, 2014, February 6, 2015 and May 7, 2015, and the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.